Last update 08 May 2025
Baiguo Yukang Information Service Co., Ltd.

Baiguo Yukang Information Service Co., Ltd.

Private Company|2016|Sichuan Sheng, China

Overview

Tags

Neoplasms
Immune System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms2
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug3
Top 5 TargetCount
PARP7(TCDD-inducible poly [ADP-ribose] polymerase)1
KRAS(GTPase KRas)1
TYK2(Tyrosine-protein kinase 2)1

Related

3
Drugs associated with Baiguo Yukang Information Service Co., Ltd.
BY-101921
Target
PARP7
Mechanism
PARP-7 inhibitors
Active Org.
Baiguo Yukang Information Service Co., Ltd.Baiguo Yukang Information Service Co., Ltd. [+2]
Originator Org.
Chengdu Baiyu Pharmaceutical Co. Ltd.Chengdu Baiyu Pharmaceutical Co. Ltd.
Active Indication
Advanced Malignant Solid Neoplasm [+1]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
CN114621244
Patent Mining
Target
KRAS
Mechanism-
Active Org.
Baiguo Yukang Information Service Co., Ltd.Baiguo Yukang Information Service Co., Ltd.
Originator Org.
Baiguo Yukang Information Service Co., Ltd.Baiguo Yukang Information Service Co., Ltd.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
CN115557947
Patent Mining
Target
TYK2
Mechanism
TYK2 inhibitors
Active Org.
Baiguo Yukang Information Service Co., Ltd.Baiguo Yukang Information Service Co., Ltd.
Originator Org.
Baiguo Yukang Information Service Co., Ltd.Baiguo Yukang Information Service Co., Ltd.
Active Indication
Autoimmune Diseases
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Baiguo Yukang Information Service Co., Ltd.
CTR20250911
/ RecruitingPhase 1/2
一项评估BY101921联合PD-1单抗在晚期恶性实体瘤患者中的安全性、耐受性、药代动力学特征及初步疗效的多中心、开放Ib/II期临床研究
[Translation] A multicenter, open-label Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BY101921 combined with PD-1 monoclonal antibody in patients with advanced malignant solid tumors
100 Clinical Results associated with Baiguo Yukang Information Service Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Baiguo Yukang Information Service Co., Ltd.
Login to view more data
100 Deals associated with Baiguo Yukang Information Service Co., Ltd.
Login to view more data
100 Translational Medicine associated with Baiguo Yukang Information Service Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
1
Phase 2 Clinical
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
BY-101921
 ( PARP7 )		Advanced Malignant Solid Neoplasm
More
Phase 2 Clinical
CN115557947
 ( TYK2 )		Autoimmune Diseases
More
Discovery
CN114621244
 ( KRAS )		Neoplasms
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free